Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAGVEN phase II study of tagraxofusp + venetoclax in treatment‑naive BPDCN
2024-511003-42-00Phase 2Authorised
- Sponsor
- French Innovative Leukemia Organization
- Start
- May 2025
- Modality
- Small Molecules, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tagraxofusp and venetoclax in Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by French Innovative Leukemia Organization. Primary endpoint: Composite complete remission after 3 TAGVEN cycles. Planned start May 2025; status: authorised.
02
Drugs
tagraxofuspvenetoclax
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on 2024-511003-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511003-42-00.